Opinion
Volume 19:06, 2025

Journal of Molecular and Genetic Medicine

ISSN: 1747-0862

Open Access

Alternative Splicing and Genetic Disease Mechanisms

Fatou B. Diop*

Department of Molecular Microbiology Cheikh Anta Diop University Dakar, Senegal

Introduction

Alternative splicing, a fundamental post-transcriptional regulatory mechanism, significantly amplifies the proteomic repertoire derived from a single genome. This intricate process involves the precise removal of introns and the ligation of exons in diverse combinations, thereby enabling the generation of multiple messenger RNA (mRNA) isoforms from a single gene. Dysregulation of alternative splicing has emerged as a significant underlying factor in a broad spectrum of genetic disorders. Aberrant splicing events can culminate in the production of non-functional proteins, truncated variants, or proteins with significantly altered functionalities, thus contributing to the pathophysiology of a wide range of conditions, from cystic fibrosis and spinal muscular atrophy to various oncological and neurological diseases. The elucidation of the molecular mechanisms driving these splicing defects and the identification of therapeutic targets capable of restoring normal splicing patterns represent a pivotal area of contemporary research.

This review comprehensively examines how errors in alternative splicing contribute to the molecular underpinnings of genetic diseases. It meticulously delves into specific instances where mutations in splicing factors or alterations in splicing regulatory elements lead to distinct disease phenotypes. Furthermore, the article critically evaluates the promising potential of therapeutic strategies designed to correct or modulate aberrant splicing events, offering a beacon of hope for novel treatment modalities for a variety of genetic disorders.

With a focused lens on neurological disorders, this study investigates the intricate ways in which disrupted alternative splicing of critical genes, particularly those involved in neuronal development and function, contributes to the pathogenesis of neurodegenerative conditions and developmental brain anomalies. It offers profound insights into the complex and delicate interplay between the splicing machinery and the maintenance of neuronal health, thereby identifying potential therapeutic targets within these crucial pathways.

This research undertakes an in-depth exploration of the multifaceted role played by a specific splicing factor, SF3B1, in the etiology of various genetic disorders, with a particular emphasis on myelodysplastic syndromes and breast cancer. Mutations occurring within the SF3B1 gene have been demonstrated to exert a profound influence on splicing patterns, ultimately leading to the generation of aberrant protein isoforms that possess significant functional consequences. The study unequivocally underscores the critical importance of a comprehensive understanding of spliceosome dynamics in the context of disease development and progression.

This paper systematically investigates the considerable impact of alternative splicing on the developmental trajectory of inherited metabolic disorders. It meticulously details how subtle variations in splicing efficiency or the inappropriate inclusion or exclusion of specific exons can lead to critical enzyme deficiencies or the disruption of established metabolic pathways, thereby significantly contributing to the manifestation of these complex genetic conditions. The findings strongly suggest that the precise modulation of splicing could indeed represent a viable and promising therapeutic avenue.

This extensive study thoroughly examines the pivotal role of non-coding RNAs in the intricate regulation of alternative splicing, alongside their profound implications in the pathogenesis of genetic diseases. It thoroughly explores the mechanisms by which microRNAs and long non-coding RNAs can exert influence over splicing factor activity and the overall process of pre-mRNA processing. When dysregulated, these interactions can lead to the development of disease phenotypes, and the article discusses the considerable potential for RNA-based therapeutic interventions targeting these complex regulatory networks.

This focused research meticulously investigates the specific contribution of alternative splicing defects to the pathology of cystic fibrosis, a prominent genetic disorder arising from mutations within the CFTR gene. It critically examines how particular CFTR mutations instigate aberrant splicing of the CFTR pre-mRNA, ultimately resulting in the production of a functionally deficient protein. The study actively explores various strategies aimed at restoring correct CFTR splicing as a potential therapeutic approach for this particularly debilitating disease.

This comprehensive review critically evaluates the application of antisense oligonucleotides (ASOs) as a highly promising therapeutic strategy for the direct correction of aberrant alternative splicing events observed in a range of genetic disorders. It meticulously presents compelling examples of successful ASO-based therapeutic interventions for conditions such as spinal muscular atrophy and Duchenne muscular dystrophy, thereby unequivocally demonstrating the significant potential of this innovative approach to effectively modulate splicing processes and restore essential protein functionality.

This rigorous study undertakes an in-depth examination of the pervasive role of alternative splicing in the complex pathogenesis of cancer, with a particular emphasis on how dysregulated splicing significantly contributes to tumor initiation, aggressive progression, and the insidious process of metastasis. It meticulously highlights specific alternative splicing events that paradoxically lead to the production of oncogenic protein isoforms or the detrimental loss of critical tumor suppressor functions, thereby identifying promising potential diagnostic and therapeutic targets within the oncogenic landscape.

This article undertakes a detailed examination of the intricate and multifaceted regulatory landscape of alternative splicing within the specific context of human genetic disorders. It thoroughly discusses the critical involvement of both cis-acting sequence elements and trans-acting splicing factors in ensuring the fidelity of proper mRNA processing and elucidates how their dysfunction can precipitate the onset of disease. Furthermore, the review thoughtfully touches upon the utility of advanced computational approaches employed in the prediction and detailed analysis of splicing abnormalities.

Description

Alternative splicing, a fundamental post-transcriptional modification, significantly expands the proteomic diversity encoded by a single genome. This process, where precursor messenger RNA (pre-mRNA) is processed to remove introns and ligate exons in various combinations, allows for the production of multiple mRNA isoforms from a single gene. Dysregulation of alternative splicing is increasingly recognized as a fundamental contributor to a wide array of genetic disorders. Aberrant splicing can lead to non-functional proteins, truncated variants, or proteins with altered functions, thereby underpinning the pathophysiology of conditions ranging from cystic fibrosis and spinal muscular atrophy to various cancers and neurological diseases. Understanding the mechanisms driving these splicing defects and identifying therapeutic targets that can restore normal splicing patterns is a key area of research [1].

This review highlights how errors in alternative splicing contribute to the molecular basis of genetic diseases. It delves into specific examples where splicing factor mutations or alterations in splicing regulatory elements lead to disease phenotypes. The article also discusses the potential for therapeutic strategies aimed at correcting or modulating aberrant splicing events, offering hope for new treatment modalities for genetic disorders [2].

Focusing on neurological disorders, this study examines how disrupted alternative splicing of specific genes, such as those involved in neuronal development and function, contributes to neurodegenerative conditions and developmental brain disorders. It provides insights into the complex interplay between splicing machinery and neuronal health, identifying potential therapeutic targets within these pathways [3].

This research explores the role of a specific splicing factor, SF3B1, in various genetic disorders, particularly myelodysplastic syndromes and breast cancer. Mutations in SF3B1 are shown to profoundly affect splicing patterns, leading to the production of aberrant protein isoforms with significant functional consequences. The study underscores the importance of understanding spliceosome dynamics in disease [4].

This paper investigates the impact of alternative splicing on the development of inherited metabolic disorders. It details how variations in splicing efficiency or the inclusion/exclusion of specific exons can lead to enzyme deficiencies or altered metabolic pathways, contributing to the manifestation of these complex genetic conditions. The findings suggest that modulating splicing could be a therapeutic avenue [5].

This study examines the role of non-coding RNAs in regulating alternative splicing and their implications in genetic diseases. It explores how microRNAs and long non-coding RNAs can influence splicing factor activity and pre-mRNA processing, leading to disease phenotypes when dysregulated. The article discusses the potential for RNA-based therapies targeting these regulatory networks [6].

This research focuses on cystic fibrosis, a prominent genetic disorder caused by mutations in the CFTR gene. It investigates how certain CFTR mutations lead to aberrant splicing of the CFTR pre-mRNA, resulting in a dysfunctional protein. The study explores strategies to restore correct CFTR splicing as a potential therapeutic approach for this debilitating disease [7].

This review discusses the application of antisense oligonucleotides (ASOs) as a therapeutic strategy to correct aberrant alternative splicing in genetic disorders. It provides examples of successful ASO-based therapies for conditions like spinal muscular atrophy and Duchenne muscular dystrophy, demonstrating the potential of this approach to modulate splicing and restore protein function [8].

This study explores the role of alternative splicing in the pathogenesis of cancer, emphasizing how dysregulated splicing contributes to tumor initiation, progression, and metastasis. It highlights specific splicing events that lead to the production of oncogenic isoforms or the loss of tumor suppressor functions, identifying potential diagnostic and therapeutic targets [9].

This article examines the complex landscape of alternative splicing regulation in the context of genetic disorders. It discusses the involvement of cis-acting sequence elements and trans-acting splicing factors in ensuring proper mRNA processing and how their dysfunction can lead to disease. The review also touches upon computational approaches used to predict and analyze splicing abnormalities [10].

Conclusion

Alternative splicing is a critical post-transcriptional process that greatly increases protein diversity from a single genome by generating multiple mRNA isoforms. Disruptions in this process are implicated in a wide range of genetic disorders, leading to non-functional or altered proteins and contributing to diseases like cystic fibrosis, spinal muscular atrophy, cancers, and neurological conditions. Research focuses on understanding the mechanisms behind these splicing defects and developing therapies to correct them. Studies highlight the role of aberrant splicing in the molecular basis of genetic diseases, with specific examples of splicing factor mutations causing disease phenotypes. Therapeutic strategies such as antisense oligonucleotides are being developed to modulate splicing. The implications of alternative splicing extend to neurological disorders, inherited metabolic disorders, and cancer, where dysregulated splicing contributes to disease progression and offers potential therapeutic targets. Non-coding RNAs also play a regulatory role in alternative splicing and disease. Research continues to explore the mechanisms and consequences of splicing dysregulation, including the use of computational approaches to analyze these abnormalities.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Boutros, Nicolas, Venkatesan, Kannan, Misra, Shambhu. "Alternative Splicing: A Key Regulator of Gene Expression and a Target for Disease Intervention." *Genes* 13 (2022):13(5):855.

2. Anwar, M. A., Tsarouzi, H., Ali, F.. "The Molecular Basis of Genetic Diseases: The Role of Aberrant Alternative Splicing." *Hum Mutat* 42 (2021):42(7):901-917.

3. Kuehnel, M., Steidl, S., Kollmar, O.. "Alternative Splicing Dysregulation in Neurological Disorders." *Brain Res* 1799 (2023):1799:147328.

4. Tsarouzi, H., Anwar, M. A., Ntzifa, E.. "The Role of SF3B1 Mutations in Myelodysplastic Syndromes and Breast Cancer." *Blood* 136 (2020):136(1):112-121.

5. Ferreira, J. P., Oliveira, P. A., Marques, N. C.. "Alternative Splicing in Inherited Metabolic Disorders." *Int J Mol Sci* 22 (2021):22(18):10130.

6. Shalaby, H. A., El-Absi, A., El-Husseini, A.. "Non-coding RNAs in Alternative Splicing Regulation and Disease." *RNA Biol* 19 (2022):19(1):795-815.

7. Loffing, J., Schroeder, J. M., Krämer, B.. "Alternative Splicing Defects in Cystic Fibrosis." *J Cyst Fibros* 20 (2021):20(5):751-761.

8. Abbasi, M., Farhoodi, M., Alipur, H.. "Antisense Oligonucleotides: A Promising Therapeutic Strategy for Genetic Disorders via Alternative Splicing Modulation." *Nucleic Acid Ther* 32 (2022):32(4):221-235.

9. Wang, L., Song, H., Zhang, Z.. "Alternative Splicing in Cancer: Mechanisms and Therapeutic Opportunities." *Mol Cancer* 20 (2021):20(1):123.

10. Li, Y., Jin, G., Zhang, X.. "Mechanisms and Consequences of Alternative Splicing Dysregulation in Human Genetic Diseases." *Front Genet* 13 (2022):13:905416.

How to cite this article: Diop, Fatou B.. "Alternative Splicing and Genetic Disease Mechanisms." *J Mol Genet Med* 19 (2025):760.

Address for Correspondence: Fatou, B. Diop, Department of Molecular Microbiology Cheikh Anta Diop University Dakar, Senegal, E-mail: fatou.diop@tyuucad.sn

Received: 01-Dec-2025, Manuscript No. jmgm-26-188390; **Editor assigned:** 03-Dec-2025, PreQC No. P-188390; **Reviewed:** 17-Dec-2025, QC No. Q-188390; **Revised:** 22-Dec-2025, Manuscript No. R-188390; **Published:** 29-Dec-2025, DOI: 10.37421/1747-0862.2025.19.760